tetano
Editor, Senior Moderator
Arch Med Res
. 2020 Aug 11;S0188-4409(20)30944-9.
doi: 10.1016/j.arcmed.2020.08.002. Online ahead of print.
A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients with COVID-19
Adeleh Sahebnasagh[SUP] 1 [/SUP], Mojataba Mojtahedzadeh[SUP] 2 [/SUP], Farhad Najmeddin[SUP] 3 [/SUP], Atabak Najafi[SUP] 4 [/SUP], Mohammadreza Safdari[SUP] 5 [/SUP], Hassan Rezai Ghaleno[SUP] 6 [/SUP], Solomon Habtemariam[SUP] 7 [/SUP], Ioana Berindan-Neagoe[SUP] 8 [/SUP], Seyed Mohammad Nabavi[SUP] 9 [/SUP]
Affiliations
Abstract
The novel coronavirus 2019-nCoV (SARS-CoV-2) infection that emerged in China in December 2019 has rapidly spread to become a global pandemic. This article summarizes the potential benefits of erythropoietin (EPO) in alleviating SARS-CoV-2 pathogenesis which is now called COVID-19. As with other coronavirus infection, the lethality of COVID-19 is associated with respiratory dysfunction due to overexpression of proinflammatory cytokines induced by the host immune responses. The resulting cytokine storm leads to the development of acute lung injury/acute respiratory distress syndrome (ALI/ARDS). Erythropoietin, well known for its role in the regulation of erythropoiesis, may have protective effects against ALI/ARDS induced by viral and other pathogens. EPO exerts antiapoptotic and cytoprotective properties under various pathological conditions. With a high safety profile, EPO promotes the production of endothelial progenitor cells and reduce inflammatory processes through inhibition of the nuclear factor-κB (NF-κB) and JAK-STAT3 signaling pathways. Thus, it may be considered as a safe drug candidate for COVID-19 patients if given at the early stage of the disease. The potential effects of erythropoietin on different aspects of ALI/ARDS associated with SARS-CoV-2 infection are reviewed.
Keywords: Acute lung injury; Acute respiratory distress syndrome; COVID-19; Erythropoietin; SARS-CoV-2.
. 2020 Aug 11;S0188-4409(20)30944-9.
doi: 10.1016/j.arcmed.2020.08.002. Online ahead of print.
A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients with COVID-19
Adeleh Sahebnasagh[SUP] 1 [/SUP], Mojataba Mojtahedzadeh[SUP] 2 [/SUP], Farhad Najmeddin[SUP] 3 [/SUP], Atabak Najafi[SUP] 4 [/SUP], Mohammadreza Safdari[SUP] 5 [/SUP], Hassan Rezai Ghaleno[SUP] 6 [/SUP], Solomon Habtemariam[SUP] 7 [/SUP], Ioana Berindan-Neagoe[SUP] 8 [/SUP], Seyed Mohammad Nabavi[SUP] 9 [/SUP]
Affiliations
- PMID: 32863034
- DOI: 10.1016/j.arcmed.2020.08.002
Abstract
The novel coronavirus 2019-nCoV (SARS-CoV-2) infection that emerged in China in December 2019 has rapidly spread to become a global pandemic. This article summarizes the potential benefits of erythropoietin (EPO) in alleviating SARS-CoV-2 pathogenesis which is now called COVID-19. As with other coronavirus infection, the lethality of COVID-19 is associated with respiratory dysfunction due to overexpression of proinflammatory cytokines induced by the host immune responses. The resulting cytokine storm leads to the development of acute lung injury/acute respiratory distress syndrome (ALI/ARDS). Erythropoietin, well known for its role in the regulation of erythropoiesis, may have protective effects against ALI/ARDS induced by viral and other pathogens. EPO exerts antiapoptotic and cytoprotective properties under various pathological conditions. With a high safety profile, EPO promotes the production of endothelial progenitor cells and reduce inflammatory processes through inhibition of the nuclear factor-κB (NF-κB) and JAK-STAT3 signaling pathways. Thus, it may be considered as a safe drug candidate for COVID-19 patients if given at the early stage of the disease. The potential effects of erythropoietin on different aspects of ALI/ARDS associated with SARS-CoV-2 infection are reviewed.
Keywords: Acute lung injury; Acute respiratory distress syndrome; COVID-19; Erythropoietin; SARS-CoV-2.